Surgery Partners stock gains 2.24 percent with Cantor at Overweight

Published on 10/08/2026 at 03:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cantor Fitzgerald reiterated an Overweight rating and USD 18.00 target on October 6, 2026. Surgery Partners stock carries a Moderate Buy consensus from 11 analysts at USD 19.00.

SGRY, US86881A1007, Illustration mit AI erstellt.

Surgery Partners stock (ISIN US86881A1007) gained 2.24 percent on October 7, 2026, while Cantor Fitzgerald reiterated its Overweight rating and USD 18.00 price target.

Cantor keeps its Overweight view

According to Investing.com on October 6, 2026, Cantor Fitzgerald maintained an Overweight rating on Surgery Partners and kept its target at USD 18.00. The report also cited a forecast of USD 0.32 earnings per share for 2026, compared with a recent loss of USD 0.69 per share.

The analyst view comes alongside operating concerns. The same Investing.com report said ambulatory surgery center and outpatient openings had remained flat since June 2026, while the average bonus declined to USD 5,100 from USD 6,400.

Revenue beat, adjusted loss remained

Surgery Partners reported second-quarter 2026 revenue of USD 848.9 million, up 2.7 percent from the year-earlier quarter, according to Investing.com. Revenue exceeded the USD 830.05 million analyst forecast, but adjusted earnings per share showed a loss of USD 0.12 against a projected profit of USD 0.06.

The result creates a mixed operating picture for the outpatient-care group. Revenue growth held up in Q2 2026, while the adjusted loss indicates that profitability and cost control remain central to the valuation case.

Targets remain above the market price

MarketBeat reported that seven analysts rated the stock Buy, three rated it Hold and one rated it Sell, producing a Moderate Buy consensus from 11 analysts with an average price target of USD 19.00. That target lies 38.6 percent above the USD 13.71 market price.

The latest strategic change is the Idaho Falls divestiture. StockTitan reported on September 17, 2026, that Surgery Partners received USD 797 million in gross proceeds and USD 587 million in net cash, while updated 2026 revenue guidance was USD 3.08 billion to USD 3.18 billion.

Stock stays below its yearly high

Surgery Partners stock was last at USD 13.71 on Nasdaq on October 7, 2026 at 4:00 p.m. ET. The price stood 41.5 percent below its 52-week high of USD 23.44 and 20.2 percent above its 52-week low of USD 11.41.